Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Itovebi (inavolisib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

PIK3CA inhibitor

Related drugs:

PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	inavolisib Sensitive: C2 – Inclusion Criteria inavolisib Sensitive : C2	inavolisib Sensitive: C2 – Inclusion Criteria inavolisib Sensitive : C2
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	inavolisib + GDC-9545 Sensitive: C3 – Early Trials inavolisib + GDC-9545 Sensitive : C3	inavolisib + GDC-9545 Sensitive: C3 – Early Trials inavolisib + GDC-9545 Sensitive : C3
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	inavolisib Resistant: D – Preclinical inavolisib Resistant : D	inavolisib Resistant: D – Preclinical inavolisib Resistant : D